Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Vanguard Growth Index Fund ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vanguard Growth Index Fund ETF trades at $88.93 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 37.5× Globus Medical Inc. Class A Common Stock's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| GMED | VUG | |
|---|---|---|
Market Cap | $10.25B | $384.60B |
Volume | 1,059,528 | 6,081,360 |
Sector | Health | Sector/Thematic |
52-Week High | $96.82 | $92.64 |
52-Week Low | $58.33 | $70.00 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VUG trades at $91.75, up 0.12% with a bullish technical outlook supported by moving averages. The ETF maintains strong historical performance with 12% average annual returns since 2004, concentrated in mega-cap technology stocks like Nvidia, Apple, and Microsoft. Recent dividend activity shows a $0.09 distribution scheduled for September 2026.
Long-term growth prospects remain favorable given VUG's track record and low expense ratio, though concentration risk in technology holdings and recent underperformance versus value funds present headwinds. The ETF suits investors with multi-decade horizons seeking large-cap growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
